CSIMarket
 
Telesis Bio Inc   (TBIO)
 

Very noticeable Deterioration in Revenues at the company over the most recent fiscal period

Telesis Bio Inc recorded fourth quarter of 2022 operating shortfall of $-7.884 millions


Published Mar 23 2023
Goran Soko / CSIMarket.com Contributer


science-2203701__340 TBIO declared disappointing most recent fiscal period, where Revenue melted down by -41.976 % to $9.47 millions and TBIO posted a shortfall per share to $-0.28, in contrast to $-0.58, in the comparable interval a year prior.

in proportion to the prior reporting period Income per Share fell from $0.21 per share and Revenue Tumbled by -86.966 % from $72.65 millions.


In the fourth quarter of 2022 Telesis Bio Inc reported net shortfall of $-8.132 million, instead of deficit of $-36.288 millions in the comparable reporting period a year ago.

Furthermore, the TBIO noted as well a shortfall of $-48.47 millions and for the financial year 2022, Revenues of $27.44 millions.

Laboratory Analytical Instruments The Laboratory Analytical Instruments company has decreased it's shortfall per share to $-1.65 from $-2.20 in the prior fiscal year, while Revenue doubled by 251.55 % from $7.80 millions a year prior.



Telesis Bio Inc's Net Income Growth

Telesis Bio Inc's Dividend Pay out





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071